No abstract

Integrating large intelligent reflecting surfaces (IRS) into millimeter-wave (mmWave) massive multi-input-multi-ouput (MIMO) has been a promising approach for improved coverage and throughput. Most existing work assumes the ideal channel estimation, which can be challenging due to the high-dimensional cascaded MIMO channels and passive reflecting elements. Therefore, this paper proposes a deep denoising neural network assisted compressive channel estimation for mmWave IRS systems to reduce the training overhead. Specifically, we first introduce a hybrid passive/active IRS architecture, where very few receive chains are employed to estimate the uplink user-to-IRS channels. At the channel training stage, only a small proportion of elements will be successively activated to sound the partial channels. Moreover, the complete channel matrix can be reconstructed from the limited measurements based on compressive sensing, whereby the common sparsity of angular domain mmWave MIMO channels among different subcarriers is leveraged for improved accuracy. Besides, a complex-valued denoising convolution neural network (CV-DnCNN) is further proposed for enhanced performance. Simulation results demonstrate the superiority of the proposed solution over state-of-the-art solutions.

No abstract

No abstract

New oral antibiotic contezolid (CZD) is effective against Gram-positive infections but unsuitable for intravenous (IV) administration due to its modest solubility. To address the medical need for an IV form of CZD, its isoxazol-3-yl phosphoramidate derivatives have been explored, and contezolid acefosamil (CZA, 8), the first representative of a novel O-acyl phosphoramidate prodrug class, has been identified. CZA exhibits high aqueous solubility (>200 mg/mL) and good hydrolytic stability at media pH suitable for IV administration. CZA rapidly converts into the active drug CZD in vivo. In a pharmacokinetic (PK) rat model, the exposure of active drug CZD after IV administration of the prodrug CZA was similar to or higher than that from the IV administration of CZD. The prodrug CZA is bioequivalent to or better than CZD in several preclinical infection models. CZA is likewise active upon its oral administration. To date, CZA has been evaluated in Phase 1 and Phase 2 clinical trials in the USA. It is advancing into further clinical studies including step-down therapy with in-hospital intravenous CZA administration followed by outpatient oral CZD treatment.